Developer docs
API playgroundTry for free, no card

Search company profiles

Verigraft AB

Full company profile

uuid00031tn

Namestring
Verigraft AB
Legal namestring
Verigraft AB
Websiteurl
verigraft.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Verigraft AB is a Swedish clinical-stage biotechnology company founded in 2014 (rooted in Karolinska Institute research) that develops personalized tissue-engineered transplants using a proprietary decellularization and recellularization platform. The technology removes donor cells and DNA from allogeneic tissue while preserving native matrix structure, then reconditions the scaffold with the patient's own biological material to produce grafts that resemble autologous tissue, eliminating transplant rejection risk and the need for lifelong immunosuppression. The lead product, P-TEV (Personalized Tissue-Engineered Vein), targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials across Spain, the Netherlands, and Poland following positive Phase I/II TECVI-1 results (11 patients treated, 82% graft functionality at 3 months, 64% at 12 months, no graft occlusions or infections). The pipeline extends the platform to arteries (P-TEA), peripheral nerves (P-TENT), and heart valves (P-TEHV).

The company monetizes through future hospital-procurement sales of ATMP products, with planned EU and US market approval by 2028. Its go-to-market relies on direct engagement with vascular surgery departments, KOL relationships, medical conference presence, and CRO partnerships (TFS HealthScience for trial execution; BBG Advanced Therapies for US manufacturing readiness). Revenue is supplemented by license partnerships, exemplified by Korean Stem Cell Bank for South Korean market access. Verigraft has secured significant non-dilutive grant funding (cumulative EU Horizon 2020, Horizon Europe, Eurostars, and Vinnova grants exceeding EUR 8M) alongside equity raises, most recently a SEK 110M capital contribution and USD 10M financing from existing investors in February-March 2026. The technology is protected by 92 granted patents extending beyond 2039.

The company operates from Gothenburg, Sweden, with a wholly-owned Spanish subsidiary (Verigraft Iberia S.L.) supporting European clinical operations, and is backed by international investors from Europe, Asia, and the United States. Headcount is in the 10-50 range, with a leadership team comprising CEO Petter Björquist (PhD, ex-AstraZeneca, ex-Cellartis/Cellectis), CTO Raimund Strehl (ex-Cellartis), CFO Edvard Nordfors, and Chairman/CMO Jan Holgersson. The target market is anchored by chronic venous insufficiency, projected to reach USD 5.95B by 2034, with additional platform applications in cardiovascular surgery, dialysis access, peripheral nerve repair, and heart valve replacement.

Short descriptiontext

Verigraft AB is a Swedish clinical-stage biotechnology company developing personalized tissue-engineered grafts using proprietary decellularization and recellularization technology, eliminating transplant rejection and immunosuppression. Its lead product P-TEV targets chronic venous insufficiency in pivotal Phase II/III trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGothenburg, Sweden
HQ citystring
Gothenburg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tissue engineering, regenerative medicine, personalized transplants, vascular grafts, biotechnology therapeutics
Industry4 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAFAF
Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine and Tissue Engineering
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales (Future)
TypeOne Time License
Description

VERIGRAFT is a clinical-stage biotechnology company that will generate revenue through sale of personalized tissue-engineered medical products. The company is developing a pipeline of products including P-TEV (veins), P-TEA (arteries), P-TEN (nerves), and P-TEHV (heart valves). Currently pre-revenue with products in clinical development.

verigraft.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1P-TEV (Personalized Tissue Engineered Vein)
Description

Lead product for treatment of chronic venous insufficiency (CVI) - personalized tissue-engineered vein with functional valve

verigraft.com
+3 more records
Core offering1 text field

VERIGRAFT develops and manufactures personalized tissue-engineered grafts using a proprietary decellularization and recellularization (DC/RC) platform that transforms donated allogeneic tissue into patient-specific transplants. Its lead product P-TEV (Personalized Tissue-Engineered Vein) targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials, with additional pipeline products for arteries (P-TEA), nerves (P-TEN), and heart valves (P-TEHV).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 82% graft functionality at 3 months, 64% at 12 months in TECVI-1 trial
+3 more records
Product overview1 text field

VERIGRAFT is a clinical-stage biotechnology company developing personalized tissue-engineered grafts using a proprietary platform that transforms donated allogeneic tissue into personalized transplants through decellularization (DC) and reconditioning/recellularization (RC) processes. The company's lead product is P-TEV (Personalized Tissue-Engineered Vein), currently in pivotal Phase II/III clinical trials for chronic venous insufficiency. The product portfolio includes P-TEA for arteries, P-TENT for peripheral nerves, and P-TEHV for heart valves. The technology eliminates transplant rejection risk and the need for lifelong immunosuppression. VERIGRAFT's pipeline spans from pre-clinical to clinical development stages, targeting vascular, cardiovascular, and neuronal diseases. The company also operates the P-TET production platform for industrialized tissue engineering.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1BBG Advanced Therapies (subsidiary of BioBridge Global)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Collaboration to support U.S. development and manufacturing readiness for VERIGRAFT's personalized tissue-engineered vein therapy (P-TEV). BBG AT provides donor vein sourcing, manufacturing, testing operations, and clinical trial preparation support in the United States. This collaboration represents strategic expansion into the U.S. market and builds on VERIGRAFT's existing European clinical experience.

globenewswire.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-28
Description

VERIGRAFT partnered with TFS HealthScience, a full-service global CRO, for the pivotal Phase II/III trial of P-TEV in patients with chronic venous insufficiency. TFS provides clinical research services across 40 countries, with specialized expertise in complex ATMP trials including manufacturing, logistics, and regulatory requirements. The partnership supports trial execution in Spain, Netherlands, and Poland.

3VISI-ON-BRAIN Doctoral Network
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-02
Description

VERIGRAFT participates as associated partner in EU-funded Horizon Europe Marie Skłodowska-Curie Doctoral Network (€4.5M EU contribution). Network focuses on advancing next-generation human in vitro and in silico approaches for complex brain disorders. VERIGRAFT contributes through collaboration and knowledge exchange.

verigraft.com
4Korean Stem Cell Bank Co. Ltd
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-10
Description

VERIGRAFT's license partner in South Korea. Researchers from Korean Stem Cell Bank visited Gothenburg for hands-on experience in manufacturing of personalized grafts as part of ongoing collaboration to expand access to patient-specific tissue therapies in the Korean market.

verigraft.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-02-18
Description

Ongoing collaboration with Tissue Engineering course at Chalmers University. VERIGRAFT hosts annual student visits providing laboratory tours and hands-on insights. Collaboration strengthens connection between academia and industry and supports pipeline of future talent.

6PREPPER Consortium (Eurostars)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-13
Description

VERIGRAFT leads PREPPER project (€1.2 million Eurostars funding) developing 3D-printed arterial grafts with partners Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska University Hospital (Sweden). Project integrates advanced 3D printing, solution-blown fiber technology, and personalized tissue engineering to create customized vascular grafts.

verigraft.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-12-18
Description

Collaboration on preclinical development of P-TEA (Personalized Tissue Engineered Arteries) and P-TEV clinical trials. Hospital provides clinical expertise and acts as partner in multiple CAMP and Vinnova-funded projects. Dr. Andrés García León serves as Principal Investigator for TECVI-1 trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-10
Description

VERIGRAFT is a founding partner of CCRM Nordic, a non-profit organization providing infrastructure for Nordic stakeholders in advanced therapies. The collaboration aims to prepare for preclinical and clinical development of VERIGRAFT's platform portfolio. CCRM Nordic will provide necessary infrastructure for future development activities.

9TELEGRAFT Consortium (EU Horizon Europe)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-12-02
Description

VERIGRAFT participates in EU-funded TELEGRAFT project (€4,352,522 total grant) to develop advanced arteriovenous graft for safe hemodialysis. Project involves 7 partners developing puncture-safe, anti-thrombotic graft with drug-releasing abilities and sensors for remote monitoring. Over 10% of population affected by chronic kidney disease.

verigraft.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Multiple collaborations with RISE including development of P-TEA platform, bioreactor technology optimization, GMP-compliant manufacturing processes, and 3D printing scaffold development. RISE provides research expertise and acts as project coordinator for various initiatives.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

VERIGRAFT collaborates with Karolinska Institutet (company origin), University of Gothenburg, multiple Vinnova-funded project consortia including CAMP (Centre for Advanced Medical Products) and Advanced Therapies Vision Driven Health Project. Also involved in 4-DBR project for brain regeneration (ATMP for deep brain reconstruction).

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage regenerative medicine company developing advanced wound care and surgical biologics. Comparable to Verigraft in regenerative medicine focus and tissue-engineered product approach, though focused on skin/wound care rather than vascular grafts.

TypeDirect peer
Description

UK-based regenerative medicine company using decellularization technology (dCELL) for tissue engineering. Highly comparable to Verigraft's core decellularization/recellularization approach across vascular, cardiac, and soft tissue applications.

TypeDirect peer
Description

Direct peer developing tissue-engineered vascular grafts using a similar regenerative medicine platform. Humacyte's bioengineered blood vessels (BioVascular Pancreas, HapMay) target vascular disease and represent the most directly comparable technology and clinical-stage approach to Verigraft's P-TEV.

4Cytograft Tissue Engineering
TypeDirect peer
Description

Tissue engineering company developing cell-based vascular grafts (Lifeline graft) for hemodialysis access. Direct competitor to Verigraft's TELEGRAFT project for dialysis vascular grafts using a similar personalized tissue-engineered approach.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company developing mesenchymal stem cell therapies for inflammatory and cardiovascular diseases including chronic heart failure. Comparable as a larger, more advanced player in the cell therapy and regenerative medicine space with overlapping cardiovascular indications.

6Athersys
TypeEmerging player
Description

Clinical-stage cell therapy company developing MultiStem cell therapy for inflammatory, neurological, and cardiovascular indications. Comparable to Verigraft as a clinical-stage advanced therapy company developing novel regenerative approaches, though using stem cells rather than tissue engineering.

TypeEmerging player
Description

Belgian clinical-stage regenerative medicine company developing tissue-engineered bone and skin products for severe tissue defects. Comparable to Verigraft as a European clinical-stage ATMP developer with platform technology for multiple tissue types.

8Pluristem Therapeutics
TypeEmerging player
Description

Clinical-stage cell therapy company developing placenta-derived cell therapies for peripheral artery disease and other vascular indications. Comparable to Verigraft's PAD application with P-TEA, though using cell therapy rather than tissue-engineered grafts.

TypeDirect peer
Description

Commercial-stage regenerative medicine company using placental tissue allografts for wound care, surgical, and orthopedic applications. Comparable to Verigraft in the broader regenerative medicine space, though focused on different tissue types and clinical applications.

TypeEmerging player
Description

Clinical-stage cell therapy company developing blood-derived stem cell therapies for critical limb ischemia and heart disease. Comparable to Verigraft's vascular applications (PAD, CVI) using autologous cell-based regenerative approaches.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verigraft AB

Regenerative Medicine and Tissue Engineeringverigraft.com

Verigraft AB is a Swedish clinical-stage biotechnology company developing personalized tissue-engineered grafts using proprietary decellularization and recellularization technology, eliminating transplant rejection and immunosuppression. Its lead product P-TEV targets chronic venous insufficiency in pivotal Phase II/III trials.

What Verigraft AB does

Verigraft AB is a Swedish clinical-stage biotechnology company founded in 2014 (rooted in Karolinska Institute research) that develops personalized tissue-engineered transplants using a proprietary decellularization and recellularization platform. The technology removes donor cells and DNA from allogeneic tissue while preserving native matrix structure, then reconditions the scaffold with the patient's own biological material to produce grafts that resemble autologous tissue, eliminating transplant rejection risk and the need for lifelong immunosuppression. The lead product, P-TEV (Personalized Tissue-Engineered Vein), targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials across Spain, the Netherlands, and Poland following positive Phase I/II TECVI-1 results (11 patients treated, 82% graft functionality at 3 months, 64% at 12 months, no graft occlusions or infections). The pipeline extends the platform to arteries (P-TEA), peripheral nerves (P-TENT), and heart valves (P-TEHV).

The company monetizes through future hospital-procurement sales of ATMP products, with planned EU and US market approval by 2028. Its go-to-market relies on direct engagement with vascular surgery departments, KOL relationships, medical conference presence, and CRO partnerships (TFS HealthScience for trial execution; BBG Advanced Therapies for US manufacturing readiness). Revenue is supplemented by license partnerships, exemplified by Korean Stem Cell Bank for South Korean market access. Verigraft has secured significant non-dilutive grant funding (cumulative EU Horizon 2020, Horizon Europe, Eurostars, and Vinnova grants exceeding EUR 8M) alongside equity raises, most recently a SEK 110M capital contribution and USD 10M financing from existing investors in February-March 2026. The technology is protected by 92 granted patents extending beyond 2039.

The company operates from Gothenburg, Sweden, with a wholly-owned Spanish subsidiary (Verigraft Iberia S.L.) supporting European clinical operations, and is backed by international investors from Europe, Asia, and the United States. Headcount is in the 10-50 range, with a leadership team comprising CEO Petter Björquist (PhD, ex-AstraZeneca, ex-Cellartis/Cellectis), CTO Raimund Strehl (ex-Cellartis), CFO Edvard Nordfors, and Chairman/CMO Jan Holgersson. The target market is anchored by chronic venous insufficiency, projected to reach USD 5.95B by 2034, with additional platform applications in cardiovascular surgery, dialysis access, peripheral nerve repair, and heart valve replacement.

Verigraft AB firmographics

Firmographics
Name
Verigraft AB
Legal name
Verigraft AB
Website
https://verigraft.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Verigraft AB is a Swedish clinical-stage biotechnology company developing personalized tissue-engineered grafts using proprietary decellularization and recellularization technology, eliminating transplant rejection and immunosuppression. Its lead product P-TEV targets chronic venous insufficiency in pivotal Phase II/III trials.
Ownership category
akta.pro rank

Verigraft AB industry classification

Industry
Product category
Regenerative Medicine and Tissue Engineering
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAFAF
Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Tissue engineering
  • Regenerative medicine
  • Personalized transplants
  • Vascular grafts
  • Biotechnology therapeutics

Where Verigraft AB is headquartered

Location

Headquarters

HQ city
Gothenburg
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Verigraft AB business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Product Sales (Future): VERIGRAFT is a clinical-stage biotechnology company that will generate revenue through sale of personalized tissue-engineered medical products. The company is developing a pipeline of products including P-TEV (veins), P-TEA (arteries), P-TEN (nerves), and P-TEHV (heart valves). Currently pre-revenue with products in clinical development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Verigraft AB product offering

Product offering

Core offering

VERIGRAFT develops and manufactures personalized tissue-engineered grafts using a proprietary decellularization and recellularization (DC/RC) platform that transforms donated allogeneic tissue into patient-specific transplants. Its lead product P-TEV (Personalized Tissue-Engineered Vein) targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials, with additional pipeline products for arteries (P-TEA), nerves (P-TEN), and heart valves (P-TEHV).

Product overview

VERIGRAFT is a clinical-stage biotechnology company developing personalized tissue-engineered grafts using a proprietary platform that transforms donated allogeneic tissue into personalized transplants through decellularization (DC) and reconditioning/recellularization (RC) processes. The company's lead product is P-TEV (Personalized Tissue-Engineered Vein), currently in pivotal Phase II/III clinical trials for chronic venous insufficiency. The product portfolio includes P-TEA for arteries, P-TENT for peripheral nerves, and P-TEHV for heart valves. The technology eliminates transplant rejection risk and the need for lifelong immunosuppression. VERIGRAFT's pipeline spans from pre-clinical to clinical development stages, targeting vascular, cardiovascular, and neuronal diseases. The company also operates the P-TET production platform for industrialized tissue engineering.

Differentiator

Problem solved

Functional benefit

Brands

  • P-TEV (Personalized Tissue Engineered Vein): Lead product for treatment of chronic venous insufficiency (CVI) - personalized tissue-engineered vein with functional valve
  • P-TEATM (Personalized Tissue Engineered Arteries)
  • P-TENTM (Personalized Tissue Engineered Nerves)
  • P-TEHVTM (Personalized Tissue Engineered Heart Valves)

Quantifiable outcome

  • 82% graft functionality at 3 months, 64% at 12 months in TECVI-1 trial
  • +3 more outcomes

Companies that use Verigraft AB

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Verigraft AB technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Verigraft AB partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, minor and major.

  • BBG Advanced Therapies (subsidiary of BioBridge Global)coreStrategic or Co-development Partner · 24 June 2026Collaboration to support U.S. development and manufacturing readiness for VERIGRAFT's personalized tissue-engineered vein therapy (P-TEV). BBG AT provides donor vein sourcing, manufacturing, testing operations, and clinical trial preparation support in the United States. This collaboration represents strategic expansion into the U.S. market and builds on VERIGRAFT's existing European clinical experience.
  • TFS HealthSciencecoreImplementation/ SI/ Consulting Partner · 28 May 2026VERIGRAFT partnered with TFS HealthScience, a full-service global CRO, for the pivotal Phase II/III trial of P-TEV in patients with chronic venous insufficiency. TFS provides clinical research services across 40 countries, with specialized expertise in complex ATMP trials including manufacturing, logistics, and regulatory requirements. The partnership supports trial execution in Spain, Netherlands, and Poland.
  • VISI-ON-BRAIN Doctoral NetworkminorStrategic or Co-development Partner · 2 March 2026VERIGRAFT participates as associated partner in EU-funded Horizon Europe Marie Skłodowska-Curie Doctoral Network (€4.5M EU contribution). Network focuses on advancing next-generation human in vitro and in silico approaches for complex brain disorders. VERIGRAFT contributes through collaboration and knowledge exchange.
  • Korean Stem Cell Bank Co. LtdcoreOEM/ Whitelabel/ Licensing Partner · 10 February 2026VERIGRAFT's license partner in South Korea. Researchers from Korean Stem Cell Bank visited Gothenburg for hands-on experience in manufacturing of personalized grafts as part of ongoing collaboration to expand access to patient-specific tissue therapies in the Korean market.
  • Chalmers University of TechnologyminorStrategic or Co-development Partner · 18 February 2025Ongoing collaboration with Tissue Engineering course at Chalmers University. VERIGRAFT hosts annual student visits providing laboratory tours and hands-on insights. Collaboration strengthens connection between academia and industry and supports pipeline of future talent.
  • PREPPER Consortium (Eurostars)majorStrategic or Co-development Partner · 13 February 2025VERIGRAFT leads PREPPER project (€1.2 million Eurostars funding) developing 3D-printed arterial grafts with partners Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska University Hospital (Sweden). Project integrates advanced 3D printing, solution-blown fiber technology, and personalized tissue engineering to create customized vascular grafts.
  • Sahlgrenska University HospitalmajorStrategic or Co-development Partner · 18 December 2024Collaboration on preclinical development of P-TEA (Personalized Tissue Engineered Arteries) and P-TEV clinical trials. Hospital provides clinical expertise and acts as partner in multiple CAMP and Vinnova-funded projects. Dr. Andrés García León serves as Principal Investigator for TECVI-1 trial.
  • CCRM NordiccoreStrategic or Co-development Partner · 10 July 2024VERIGRAFT is a founding partner of CCRM Nordic, a non-profit organization providing infrastructure for Nordic stakeholders in advanced therapies. The collaboration aims to prepare for preclinical and clinical development of VERIGRAFT's platform portfolio. CCRM Nordic will provide necessary infrastructure for future development activities.
  • TELEGRAFT Consortium (EU Horizon Europe)majorStrategic or Co-development Partner · 2 December 2022VERIGRAFT participates in EU-funded TELEGRAFT project (€4,352,522 total grant) to develop advanced arteriovenous graft for safe hemodialysis. Project involves 7 partners developing puncture-safe, anti-thrombotic graft with drug-releasing abilities and sensors for remote monitoring. Over 10% of population affected by chronic kidney disease.
  • RISE Research Institutes of SwedenmajorStrategic or Co-development PartnerMultiple collaborations with RISE including development of P-TEA platform, bioreactor technology optimization, GMP-compliant manufacturing processes, and 3D printing scaffold development. RISE provides research expertise and acts as project coordinator for various initiatives.
  • Multiple Academic & Research PartnersmajorStrategic or Co-development PartnerVERIGRAFT collaborates with Karolinska Institutet (company origin), University of Gothenburg, multiple Vinnova-funded project consortia including CAMP (Centre for Advanced Medical Products) and Advanced Therapies Vision Driven Health Project. Also involved in 4-DBR project for brain regeneration (ATMP for deep brain reconstruction).

Scale indicators8 records

Recent moves4 records

Expansion highlights6 records

Verigraft AB competitors and assessment

Company assessment

Direct peers

  • Organogenesis Holdings: Commercial-stage regenerative medicine company developing advanced wound care and surgical biologics. Comparable to Verigraft in regenerative medicine focus and tissue-engineered product approach, though focused on skin/wound care rather than vascular grafts.
  • Tissue Regenix Group: UK-based regenerative medicine company using decellularization technology (dCELL) for tissue engineering. Highly comparable to Verigraft's core decellularization/recellularization approach across vascular, cardiac, and soft tissue applications.
  • Humacyte: Direct peer developing tissue-engineered vascular grafts using a similar regenerative medicine platform. Humacyte's bioengineered blood vessels (BioVascular Pancreas, HapMay) target vascular disease and represent the most directly comparable technology and clinical-stage approach to Verigraft's P-TEV.
  • Cytograft Tissue Engineering: Tissue engineering company developing cell-based vascular grafts (Lifeline graft) for hemodialysis access. Direct competitor to Verigraft's TELEGRAFT project for dialysis vascular grafts using a similar personalized tissue-engineered approach.
  • MiMedx Group: Commercial-stage regenerative medicine company using placental tissue allografts for wound care, surgical, and orthopedic applications. Comparable to Verigraft in the broader regenerative medicine space, though focused on different tissue types and clinical applications.

Broad incumbents

  • Mesoblast: Commercial-stage regenerative medicine company developing mesenchymal stem cell therapies for inflammatory and cardiovascular diseases including chronic heart failure. Comparable as a larger, more advanced player in the cell therapy and regenerative medicine space with overlapping cardiovascular indications.

Emerging players

  • Athersys: Clinical-stage cell therapy company developing MultiStem cell therapy for inflammatory, neurological, and cardiovascular indications. Comparable to Verigraft as a clinical-stage advanced therapy company developing novel regenerative approaches, though using stem cells rather than tissue engineering.
  • Novadip Biosciences: Belgian clinical-stage regenerative medicine company developing tissue-engineered bone and skin products for severe tissue defects. Comparable to Verigraft as a European clinical-stage ATMP developer with platform technology for multiple tissue types.
  • Pluristem Therapeutics: Clinical-stage cell therapy company developing placenta-derived cell therapies for peripheral artery disease and other vascular indications. Comparable to Verigraft's PAD application with P-TEA, though using cell therapy rather than tissue-engineered grafts.
  • Hemostemix: Clinical-stage cell therapy company developing blood-derived stem cell therapies for critical limb ischemia and heart disease. Comparable to Verigraft's vascular applications (PAD, CVI) using autologous cell-based regenerative approaches.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Verigraft AB social profiles

Digital presence

Verigraft AB financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verigraft AB leadership team

Management profile

Number of profiles

Profiles1 record

Verigraft AB subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Verigraft AB funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verigraft AB M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verigraft AB

What does Verigraft AB do?

VERIGRAFT develops and manufactures personalized tissue-engineered grafts using a proprietary decellularization and recellularization (DC/RC) platform that transforms donated allogeneic tissue into patient-specific transplants. Its lead product P-TEV (Personalized Tissue-Engineered Vein) targets chronic venous insufficiency and is currently in pivotal Phase II/III clinical trials, with additional pipeline products for arteries (P-TEA), nerves (P-TEN), and heart valves (P-TEHV).

Is Verigraft AB a public or private company?

Verigraft AB is a private company. It is classified as venture growth investor backed and is currently operating.

When was Verigraft AB founded?

Verigraft AB was founded in 2014. It employs 11 to 50 people.

Where is Verigraft AB based?

Verigraft AB is headquartered in Gothenburg, Sweden, in the Europe region.

How does Verigraft AB make money?

One revenue line is on record: product Sales (Future).

Who are Verigraft AB's main competitors?

Direct peers on record are Organogenesis Holdings, Tissue Regenix Group, Humacyte, Cytograft Tissue Engineering and MiMedx Group. Mesoblast is listed as a broad incumbent. Emerging players are Athersys, Novadip Biosciences, Pluristem Therapeutics and Hemostemix.

Does Verigraft AB have an API?

No public API is recorded for Verigraft AB.

What industry is Verigraft AB in?

Verigraft AB's product category is Regenerative Medicine and Tissue Engineering. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerRatos subsidiary TFS HealthScience to support Verigraft studyTFS HealthScience, a Ratos subsidiary, will provide full-service clinical research support for the Verigraft study, which evaluates the safety, function, and long-term performance of the treatment in a larger patient cohort. Ratos holds a 100 percent stake in TFS HealthScience.news.cision.comVERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III TrialVERIGRAFT has initiated a pivotal Phase II/III clinical trial for its P-TEV (personalized tissue engineered vein) treatment for chronic venous insufficiency, backed by USD 10 million in financing from existing investors. The trial, with sites in Spain, the Netherlands, and Poland, targets a multi-million patient population with no existing curative treatment, with the company aiming for US and European market approval in 2028. The fully biological transplant approach eliminates the need for immunosuppression and uses a proprietary 10-day manufacturing process protected by 92 granted patents.PR NewswireVERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III TrialVERIGRAFT, a Swedish clinical-stage biotechnology company, announced the initiation of a pivotal Phase II/III clinical trial for its personalized tissue-engineered vein (P-TEV) to treat chronic venous insufficiency (CVI), with trial sites located in Spain, the Netherlands, and Poland. The company secured USD 10 million in financing from existing investors to support the trial, which aims for market approval in both Europe and the US by 2028. The fully biological therapy eliminates the need for immunosuppression and is protected by 92 granted patents, with the CVI market projected to reach USD 5,951 million by 2034.VerigraftVERIGRAFT announces committed SEK 110m capital contributionVERIGRAFT AB announced a committed capital contribution of SEK 110 million from an existing long-term shareholder to advance its pivotal trial program in Europe and the United States. The funding will support Phase II/III trial preparation, regulatory submissions, manufacturing readiness, and clinical infrastructure, extending the company's financial flexibility as it approaches multiple value-creating milestones. CEO Petter Björquist stated the investment reflects strong long-term conviction from a shareholder with deep insight into VERIGRAFT's development plan.EIN PresswireVERIGRAFT Reports Strong Safety and Favorable Clinical Outcomes in First-in-Human TECVI-1 TrialVERIGRAFT AB announced results from its first-in-human TECVI-1 clinical trial evaluating the Personalized Tissue-Engineered Vein (P-TEV) in patients with severe chronic venous insufficiency, demonstrating very good safety outcomes and encouraging clinical improvements over 12 months of follow-up. The trial showed significant and sustained symptom improvements measured by the Venous Clinical Severity Score, along with ulcer healing and stable quality-of-life scores, with no unexpected safety signals observed. The company is now preparing to advance to a multicenter pivotal trial focused on long-term efficacy, durability, and scalability.VerigraftVERIGRAFT secures Eurostars grant to advance personalized 3D-printed arterial graftsVERIGRAFT received a Eurostars grant to lead PREPPER, a project developing 3D-printed arterial grafts with Readily3D, RISE, and Sahlgrenska University Hospital. The €1.2 million project aims to create personalized vascular grafts, with a first-in-human trial planned. The global vascular graft market is projected to exceed $4 billion by 2026.VerigraftDon’t miss the chance to invest early in VERIGRAFT’s mission to create “custom-made spare parts” for the human bodyVERIGRAFT launched a crowdfunding campaign on Capital Cell to fund its personalized tissue therapy for vascular disease. The company aims to expand clinical trials and develop its pipeline of personalized tissue grafts. The campaign seeks to raise funds to accelerate future treatments.ArcticstartupSwedish VERIGRAFT secures Eurostars grant to advance 3D-printed vascular solutionsSwedish biotech company VERIGRAFT has secured a €1.2 million Eurostars grant to advance its PREPPER project, which aims to develop 3D-printed arterial grafts that better mimic natural arteries. The project is a collaboration with Readily3D SA (Switzerland), RISE, and Sahlgrenska University Hospital (Sweden), and could lead to a first-in-human clinical trial. The global vascular graft market is projected to exceed $4 billion by 2026, and the technology may have broader applications in regenerative medicine.Tech.euSwedish biotech VERIGRAFT secures €1.2M from Eurostars to advance 3D-printed arterial graftsSwedish biotech VERIGRAFT received a €1.2M Eurostars grant to lead PREPPER, developing 3D-printed arterial grafts. The project aims to overcome graft limitations and could lead to a first-in-human trial. VERIGRAFT has already transplanted its P-TEVTM vein graft into patients with CVI, with one patient walking unaided.